Anti–Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema
-
Published:2021-11
Issue:
Volume:
Page:
-
ISSN:0161-6420
-
Container-title:Ophthalmology
-
language:en
-
Short-container-title:Ophthalmology
Author:
Leclercq MathildeORCID,
Andrillon Anaïs,
Maalouf Georgina,
Sève Pascal,
Bielefeld Philip,
Gueudry JulieORCID,
Sené Thomas,
Moulinet Thomas,
Rouvière Bénédicte,
Sène Damien,
Desbois Anne-Claire,
Domont Fanny,
Touhami Sara,
El Chamieh CarollaORCID,
Cacoub Patrice,
Bodaghi Bahram,
Biard Lucie,
Saadoun David
Reference35 articles.
1. Prevalence of noninfectious uveitis in the United States: a claims-based analysis;Thorne;JAMA Ophthalmol,2016
2. A focus on the epidemiology of uveitis;Tsirouki;Ocul Immunol Inflamm,2018
3. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis;Dick;Ophthalmology,2016
4. Risk factors for ocular complications in adult patients with uveitis;Prieto-Del-Cura;Eur J Ophthalmol,2020
5. Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges;Massa;Clin Ophthalmol Auckl N Z,2019
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献